Treatment of prostate cancer confronts resistance to androgen receptor (AR)-targeted therapies. AR-associated coregulators and chromatin proteins hold a great potential for novel therapy targets. Here, we employed a powerful chromatin-directed proteomics approach termed ChIP-SICAP to uncover the composition of chromatin protein network, the chromatome, around endogenous AR in castration resistant prostate cancer (CRPC) cells. In addition to several expected AR coregulators, the chromatome contained many nuclear proteins not previously associated with the AR. In the context of androgen signaling in CRPC cells, we further investigated the role of a known AR-associated protein, a chromatin remodeler SMARCA4 and that of SIM2, a transcription fa...
The androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is the commone...
SummaryThe androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is the ...
BACKGROUND: The androgen receptor (AR) is a major drug target in prostate cancer (PCa). We profiled ...
Treatment of prostate cancer confronts resistance to androgen receptor (AR)-targeted therapies. AR-a...
UnrestrictedThe androgen receptor (AR) has unequivocal roles throughout all phases of prostate cance...
Global changes in chromatin accessibility may drive cancer progression by reprogramming transcriptio...
Global changes in chromatin accessibility may drive cancer progression by reprogramming transcriptio...
Prostate cancer (PCa) is the second most common cancer affecting men worldwide. PCa shows a broad-sp...
AbstractProstate cancer (PCa) is the second most common cancer in men. The Androgen Receptor (AR) is...
Global changes in chromatin accessibility may drive cancer progression by reprogramming transcriptio...
Prostate cancer (PCa) is the second most common cancer in men. The Androgen Receptor (AR) is the maj...
This review will provide a description of recent efforts in our laboratory contributing to a general...
Androgen signaling via the androgen receptor (AR) is involved in normal prostate development and pro...
The androgen receptor (AR) is a ligand-dependent transcription factor. Binding of androgens induces...
BACKGROUND: The androgen receptor (AR) is a major drug target in prostate cancer (PCa). We profiled ...
The androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is the commone...
SummaryThe androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is the ...
BACKGROUND: The androgen receptor (AR) is a major drug target in prostate cancer (PCa). We profiled ...
Treatment of prostate cancer confronts resistance to androgen receptor (AR)-targeted therapies. AR-a...
UnrestrictedThe androgen receptor (AR) has unequivocal roles throughout all phases of prostate cance...
Global changes in chromatin accessibility may drive cancer progression by reprogramming transcriptio...
Global changes in chromatin accessibility may drive cancer progression by reprogramming transcriptio...
Prostate cancer (PCa) is the second most common cancer affecting men worldwide. PCa shows a broad-sp...
AbstractProstate cancer (PCa) is the second most common cancer in men. The Androgen Receptor (AR) is...
Global changes in chromatin accessibility may drive cancer progression by reprogramming transcriptio...
Prostate cancer (PCa) is the second most common cancer in men. The Androgen Receptor (AR) is the maj...
This review will provide a description of recent efforts in our laboratory contributing to a general...
Androgen signaling via the androgen receptor (AR) is involved in normal prostate development and pro...
The androgen receptor (AR) is a ligand-dependent transcription factor. Binding of androgens induces...
BACKGROUND: The androgen receptor (AR) is a major drug target in prostate cancer (PCa). We profiled ...
The androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is the commone...
SummaryThe androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is the ...
BACKGROUND: The androgen receptor (AR) is a major drug target in prostate cancer (PCa). We profiled ...